One of the most renowned pharmaceutical and biotechnology firms in the world is Bayer. It is renowned for developing everyday items like aspirin as well as cutting-edge breakthroughs and technology that are frequently utilized in the background, such as dyes for radiological examinations and vital crop/plant bio-products.
Despite being close to 150 years old, the company is dedicated to enhancing patient care and is constantly innovating and growing its global effect.
Its considerable use of AI, notably in collaboration with Google Cloud to optimize its core pharmaceutical business, is one of its most recent endeavors.
This effort uses Google Cloud’s Tensor Processing Units (TPUs) to enhance the clinical trial and drug development processes, which is one of its main areas of interest. TPUs are application-specific integrated circuits (ASICs) that Google developed specifically to speed up machine learning workloads. Cloud TPU is a web service that gives users access to these through Google Cloud and may be used to train lengthy machine learning models and carry out big matrix operations. Bayer intends to use this technology to carry out massive quantum chemistry simulations and thereby get new insights.
Bayer will also improve the laborious clinical trial procedure using Med-PaLM 2 and Vertex AI from Google Cloud. In particular, these tools will be able to more effectively interpret big data sets, discover connections between unrelated data points, and produce insights that will improve the research and development process.
I spoke with Guido Mathews, Head of Imaging, Data, and the AI Research Centre of Excellence at Bayer, on how AI can effectively utilize the enormous quantity of data that R&D frequently entails while also streamlining, speeding up, and scaling the entire process. In addition, he asserts that one of the most beneficial uses of AI will be to assist in the generation of regulatory documentation, which is currently one of the most difficult tasks in research. To ensure strict compliance, regulatory agencies frequently request voluminous paperwork and documentation related to clinical trials. It takes a lot of time and money to prepare this documentation, which frequently necessitates considerable information gathering and submission in a predetermined manner. Artificial intelligence (AI) offers a significant potential to automate parts of these procedures by employing the technology to elegantly package the documentation for submission by synthesizing and summarising content, organizing references, and so forth.
Additionally, Mathews explains how Bayer hopes to use AI to improve radiology: “Imaging and medical procedures have significantly increased, and the field of radiology is expanding. AI can assist radiologists in achieving better results, identifying more accurate findings, and ultimately giving patients better care. To realize this ambition, Bayer now has access to the technology, healthcare know-how, and cutting-edge models through this expanded relationship with Google Cloud.
Furthermore, Bayer’s ambitions to develop in radiography come at an ideal time as the discipline increasingly positions itself for cooperation with AI. Numerous research studies have demonstrated the enormous potential at the interface between AI and radiology; for example, only this summer, a well-known study discovered that AI algorithms outperformed standardized risk models in radiological breast cancer predictions.
Undoubtedly, Bayer’s expanding goals in this area will benefit greatly from its relationship with Google Cloud.
According to Shweta Maniar, Director of Healthcare & Life Sciences Solutions at Google Cloud, Bayer is taking a huge stride ahead by employing Google Cloud’s TPUs for quantum computing. She also says that generative AI is helpful for the life sciences because Vertex AI offers new opportunities for picture understanding, ambient documentation, and language understanding. Vertex AI search offers the chance to build personalized chatbots and give organizations a new method to interact with data and insight development. Overall, this technology has the potential to revolutionize the biotechnology and life sciences industries.
In keeping with this, she adds, “We don’t want to hasten this process. Generative AI is generating a lot of excitement, but to advance this technology, we must take the proper measures. We are concentrating on keeping the human in the loop and creating this technology safely and sustainably, as slow and time-consuming as that may be. She further emphasizes Google Cloud’s dedication to responsible and secure development by describing the extensive internal testing that takes place before the business makes the technology available to users and partners.
In the end, this is just the start for Bayer and its collaboration with Google Cloud. The applications for this technology and the value that it may contribute to patient lives are truly limitless with the proper testing, development, and deployment.
